StrimvelisTM receives European marketing authorisation to treat very rare disease ADA-SCID

Strimvelis, (autologous CD34+ cells transduced to express ADA) the first ex vivo stem cell gene therapy has been approved to treat patients with ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency). Children born with ADA-SCID do not have a heathy, fully functioning immune system and are unable to successfully combat everyday infections.

www.gsk.com › en-gb › Media › Press releases

Prime GlobalStrimvelisTM receives European marketing authorisation to treat very rare disease ADA-SCID
Share this post

Join the conversation

Related Posts